← Browse by Condition
Medical Condition
locally advanced pancreatic adenocarcinoma
Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 3
ClinicalMetric tracks all active clinical trials for locally advanced pancreatic adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — locally advanced pancreatic adenocarcinoma Clinical Trials
How many clinical trials are currently recruiting for locally advanced pancreatic adenocarcinoma?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for locally advanced pancreatic adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for locally advanced pancreatic adenocarcinoma?
locally advanced pancreatic adenocarcinoma research spans Phase 1 (2 trials), Phase 2 (4 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a locally advanced pancreatic adenocarcinoma clinical trial?
Eligibility criteria for locally advanced pancreatic adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 4
Phase 3 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT04570943 Phase 2
Recruiting
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Enrollment
103 pts
Location
France
Sponsor
Institut du Cancer de Montpell...
NCT07157033 Phase 1, Phase 2
Recruiting
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
Enrollment
36 pts
Location
United States
Sponsor
Xerient Pharma
NCT06381154 Phase 2
Recruiting
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Enrollment
25 pts
Location
United States
Sponsor
Mayo Clinic
NCT04172532 Phase 1, Phase 2
Recruiting
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Enrollment
92 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT05679674
Recruiting
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
Enrollment
48 pts
Location
United States
Sponsor
Baptist Health South Florida
NCT06998940 Phase 3
Recruiting
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Enrollment
94 pts
Location
United States
Sponsor
SWOG Cancer Research Network
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology